TSXV:CLAS.H - Post by User
Post by
mattusvion Jul 20, 2020 9:04am
142 Views
Post# 31289576
Related
Related
NIA is aware of a small-cap Canadian listed company BetterLife Pharma (CSE: BETR) with a U.S. symbol BETRD that is currently trading for $1.89 per share with a market cap of only US$24.1 million and its wholly owned BLife Therapeutics is planning clinical trials of AP-003 to test the efficacy of IFNa2b for treatment of COVID-19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.
Synairgen's market cap this morning has increased from US$68.87 million up to a current market cap of US$378.72 million and we believe BETR's AP-003 is superior to Synairgen's SNG001!
BETR is in the midst of securing clearance to initiate a Phase II study of AP-003 against COVID-19 this summer. BETRhopes that an inhaler delivering AP-003 directly to a patient’s lungs could make a difference by not only treating those who are seriously ill in the hospital, but by eventually also being used as a coronavirus prophylaxis/prevention, allowing sufferers and those at high risk the ability to treat themselves at home before even becoming ill!